<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Korean J Ophthalmol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Korean J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">KJO</journal-id>
      <journal-title-group>
        <journal-title>Korean Journal of Ophthalmology : KJO</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1011-8942</issn>
      <issn pub-type="epub">2092-9382</issn>
      <publisher>
        <publisher-name>The Korean Ophthalmological Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24688265</article-id>
      <article-id pub-id-type="pmc">3958638</article-id>
      <article-id pub-id-type="doi">10.3341/kjo.2014.28.2.189</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Acetazolamide for Cystoid Macular Oedema in Bietti Crystalline Retinal Dystrophy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Broadhead</surname>
            <given-names>Geoffrey K</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Chang</surname>
            <given-names>Andrew A</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Sydney Institute of Vision Science, Sydney, Australia.</aff>
      <aff id="A2"><label>2</label>Sydney Retina Clinic &amp; Day Surgery, Sydney, Australia.</aff>
      <aff id="A3"><label>3</label>Save Sight Institute, The University of Sydney, Sydney, Australia.</aff>
      <author-notes>
        <corresp>
Corresponding Author: Andrew A Chang, PhD. Sydney Retina Clinic &amp; Day Surgery, Level 13, Park House, 187 Macquarie Street, Sydney, 2000, NSW, Australia. Tel: 61-2-9221-3755, Fax: 61-2-9221-1637, <email>achang@sydneyretina.com.au</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>3</month>
        <year>2014</year>
      </pub-date>
      <volume>28</volume>
      <issue>2</issue>
      <fpage>189</fpage>
      <lpage>191</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>10</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>2</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2014 The Korean Ophthalmological Society</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Bietti crystalline retinal dystrophy is a rare, inherited disorder whose hallmark is the presence of retinal crystal deposits associated with later chorioretinal degeneration. This condition may rarely be complicated by the development of cystoid macular oedema leading to rapid visual decline. Currently, treatment options for this complication of Bietti dystrophy are limited and the visual prognosis is poor. Here, we present a case of cystoid macular oedema associated with Bietti dystrophy that was successfully diagnosed using multimodal imaging techniques including optical coherence tomography and fluorescein angiography. These modalities confirmed the diagnosis of macular oedema and excluded other possible causes of oedema such as choroidal neovascularisation. In this patient, cystoid macular oedema was resolved with oral acetazolamide therapy, a treatment that has not been previously reported in this context. Acetazolamide treatment resulted in oedema resolution and improvement in visual function, and can be considered a therapeutic option for other patients with Bietti dystrophy who develop cystoid macular oedema.</p>
      </abstract>
      <kwd-group>
        <kwd>Acetazolamide</kwd>
        <kwd>Bietti crystalline dystrophy</kwd>
        <kwd>Macular edema</kwd>
        <kwd>Optical coherence tomography</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Bietti crystalline retinal dystrophy is a rare, autosomal, recessively inherited disorder that is more common in patients of East Asian descent. This disease is characterised by the deposition of yellow crystals in the corneal limbus and retina, leading to the development of retinal and choroidal atrophy with resultant visual deterioration [<xref rid="B1" ref-type="bibr">1</xref>]. Optical coherence tomography (OCT) may show reflective deposits suggestive of crystalline deposits, and fundus fluorescein angiography (FFA) often demonstrates characteristic retinal pigment epithelium (RPE) atrophy [<xref rid="B2" ref-type="bibr">2</xref>]. This condition may also rarely be associated with choroidal neovascularisation (CNV) [<xref rid="B3" ref-type="bibr">3</xref>]. The prognosis for this disease is generally poor, with visual decline often progressing to blindness.</p>
    <p>Mutations in the <italic>CYP4V2</italic> gene, which produces proteins involved in one of the many cytochrome P450 proteins, have been identified as being linked to Bietti dystrophy [<xref rid="B4" ref-type="bibr">4</xref>]. Linkage analysis suggests that the affected protein may be involved in fatty acid metabolism [<xref rid="B4" ref-type="bibr">4</xref>]. Given that the crystals that are pathognomonic of this disease are thought to be composed of lipids and lipid by-products [<xref rid="B1" ref-type="bibr">1</xref>], it is possible that aberrant cytochrome P450 function results in problems with lipid metabolism in retinal tissues, causing crystal deposition. These crystals may then impair cellular function, leading to progressive chorioretinal atrophy.</p>
    <sec>
      <title>Case Report</title>
      <p>A 32-year-old male of Maltese heritage who was known to have electroretinogram-confirmed Bietti crystalline retinal dystrophy presented with acute bilateral central visual impairment. Upon examination, best-corrected visual acuity (BCVA) was 6 / 60 in the right eye and 6 / 45 in the left eye. At an examination one year previously, BCVA had been 6 / 7.5 in the right eye and 6 / 18 in the left.</p>
      <p>Dilated retinal examination revealed the presence of peripheral corneal and retina crystalline changes characteristic of Bietti dystrophy (<xref ref-type="fig" rid="F1">Fig. 1A and 1B</xref>). Flourescein angiography showed patchy hypof luorescence indicative of chorioretinal atrophy. No evidence of late leakage was observed, excluding the diagnosis of choroidal neovascularisation (<xref ref-type="fig" rid="F1">Fig. 1C-1F</xref>). Time-domain (TD)-OCT was performed and demonstrated bilateral cystic macular lesions (<xref ref-type="fig" rid="F1">Fig. 1G and 1H</xref>) with a central foveal thickness (CFT) of 242 &#xB5;m in the right eye and 253 &#xB5;m in the left.</p>
      <p>On the basis of the OCT findings, the patient was diagnosed with cystoid macular oedema. Acetazolamide therapy at a dose of 500 mg daily was initiated, and one month later, visual acuity improved to 6 / 18 bilaterally and CFT reduced to 221 &#xB5;m in the right eye and 225 &#xB5;m in the left eye. Following one year of acetazolamide therapy, BCVA was 6 / 15 in the right eye and 6 / 24 in the left eye, and CFT had stabilised at 221 &#xB5;m in the right eye and 219 &#xB5;m in the left eye (<xref ref-type="fig" rid="F1">Fig. 1I and 1J</xref>).</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Bietti crystalline retinal dystrophy is an uncommon, inherited, retinal degeneration associated with retinal crystal deposits and progressive visual decline. Cystoid macular oedema is a rare complication of this disease, and may be associated with an acceleration of visual loss [<xref rid="B5" ref-type="bibr">5</xref>]. The pathogenesis of the oedema in this disorder is not well understood, and therefore treatment options are limited.</p>
      <p>Macular oedema has been documented in association with other inherited retinal dystrophies, notably retinitis pigmentosa [<xref rid="B6" ref-type="bibr">6</xref>]. In this setting, it is considered that the oedema may relate to impaired RPE function, resulting in a failure of the RPE pumping mechanism [<xref rid="B7" ref-type="bibr">7</xref>]. Inhibition of carbonic anhydrase with acetazolamide has previously been shown to result in increased retinal pump activity [<xref rid="B7" ref-type="bibr">7</xref>], and has been used in this regard to treat cystoid macular oedema associated with retinitis pigmentosa [<xref rid="B6" ref-type="bibr">6</xref>], X-linked retinoschisis [<xref rid="B8" ref-type="bibr">8</xref>] and enhanced S-cone syndrome [<xref rid="B9" ref-type="bibr">9</xref>] with some success.</p>
      <p>To our knowledge, this is the first case of cystoid macular oedema associated with Bietti dystrophy that was successfully treated with acetazolamide therapy in the literature. Given the reversible nature of this complication, it is important that potential treatments be recognised to preserve optimal vision.</p>
      <p>Patients with Bietti dystrophy who develop worsening central vision should be promptly assessed to diagnose cystoid macular oedema. This complication is responsive to therapy with acetazolamide, resulting in improved anatomical outcomes and preservation of visual function.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>No potential conflict of interest relevant to this article was reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Weleber</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>ML</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bietti's crystalline dystrophy. A clinicopathologic correlative study</article-title>
          <source>Arch Ophthalmol</source>
          <year>1989</year>
          <volume>107</volume>
          <fpage>213</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="pmid">2783846</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rossi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Testa</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and genetic features in Italian Bietti crystalline dystrophy patients</article-title>
          <source>Br J Ophthalmol</source>
          <year>2013</year>
          <volume>97</volume>
          <fpage>174</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="pmid">23221965</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Atmaca</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Muftuoglu</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Atmaca-Sonmez</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Peripapillary choroidal neovascularization in Bietti crystalline retinopathy</article-title>
          <source>Eye (Lond)</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>839</fpage>
          <lpage>842</lpage>
          <pub-id pub-id-type="pmid">17173010</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jiao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Munier</surname>
              <given-names>FL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2</article-title>
          <source>Am J Hum Genet</source>
          <year>2004</year>
          <volume>74</volume>
          <fpage>817</fpage>
          <lpage>826</lpage>
          <pub-id pub-id-type="pmid">15042513</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parravano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sciamanna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giorno</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bietti crystalline dystrophy: a morpho-functional evaluation</article-title>
          <source>Doc Ophthalmol</source>
          <year>2012</year>
          <volume>124</volume>
          <fpage>73</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">22205354</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fishman</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Fiscella</surname>
              <given-names>RG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa</article-title>
          <source>Arch Ophthalmol</source>
          <year>1989</year>
          <volume>107</volume>
          <fpage>1445</fpage>
          <lpage>1452</lpage>
          <pub-id pub-id-type="pmid">2803090</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolfensberger</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Chiang</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marmor</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>2000</year>
          <volume>238</volume>
          <fpage>76</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">10664057</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghajarnia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gorin</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Acetazolamide in the treatment of X-linked retinoschisis maculopathy</article-title>
          <source>Arch Ophthalmol</source>
          <year>2007</year>
          <volume>125</volume>
          <fpage>571</fpage>
          <lpage>573</lpage>
          <pub-id pub-id-type="pmid">17420384</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iannaccone</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Eyestone</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide</article-title>
          <source>Am J Ophthalmol</source>
          <year>2009</year>
          <volume>147</volume>
          <fpage>307</fpage>
          <lpage>312.e2</lpage>
          <pub-id pub-id-type="pmid">18835469</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Images from the patient demonstrating crystalline retinopathy. (A) Fundus photograph of the right eye, (B) fundus photograph of the left eye, (C) early-phase fundus fluorescein angiogram (FFA) of the right eye, (D) early-phase FFA of the left eye, (E) late-phase FFA of the right eye, (F) late-phase FFA of the left eye, (G) baseline time-domain optical coherence tomography (TD-OCT) image of the right eye, (H) baseline TD-OCT image of the left eye, (I) 1-year post-treatment TD-OCT image of the right eye, and (J) 1-year post-treatment TD-OCT image of the left eye.</p>
      </caption>
      <graphic xlink:href="kjo-28-189-g001"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
